Status:
COMPLETED
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Collaborating Sponsors:
Gesellschaft für Therapieforschung mbH
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
Brief Summary
The aim of this case series was to document the effectiveness and compatibility of Rebif 44 or 22 µg in the therapy of the chronic multiple sclerosis (MS) under practical conditions on a large collect...
Detailed Description
Interferon beta-1a is established as therapy of the first choice in the treatment of the chronic MS. The PRISMS study has shown that the therapy with Rebif reduces the frequency and seriousness of cli...
Eligibility Criteria
Inclusion
- Subjects with clinically safe diagnosis of a chronic MS and ability to walk (also with aids).
Exclusion
- Subjects with primary chronically progressive course of the MS
- Pregnant or nursing female subjects
- Subjects with severe depressions
- Epilepsy subjects whose symptoms cannot be cured adequately with therapy
- Subjects with existing systemic concurrent diseases (e.g. diabetes, heart, liver, kidney diseases)
Key Trial Info
Start Date :
June 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
522 Patients enrolled
Trial Details
Trial ID
NCT01142557
Start Date
June 1 2004
End Date
November 1 2005
Last Update
July 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Merck Serono GmbH
Darmstadt, Germany, 64289